Fact sheet: BB Biotech

Fund information

Fund name
BB Biotech B USD
Fund company manager
Bellevue Asset Management
Fund type
SIB
Fund manager
Lydia Bänziger
since 02/01/2012
Fund objective
The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.
Benchmark
Nasdaq Biotech Index
Investment style
Active,Growth
Investment method
Shares

Quick stats

1 Year return

7.66 %

1 Year rank in sector

12/29

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 57.7 m

FE Risk score

231

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    97.9%
  • Others
    1.4%
  • Money Market
    0.7%
  • Health Care
    57.9%
  • Pharmaceuticals
    16%
  • Healthcare & Medical Products
    14.3%
  • Others
    7.3%
  • Biotechnology/Medical
    3.8%
  • US Equities
    97.9%
  • Money Market
    1.4%
  • International Equities
    0.7%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund-1.71 %5.64 %7.66 %14.09 %123.74 %
Sector-2.14 %3.95 %6.57 %24.27 %99.62 %
Rank within sector15 / 3011 / 2912 / 2918 / 266 / 23
Quartile th2 nd2 nd2 nd3 rd2 nd

Calendar performance

YTD-20172016201520142013
Fund20.03 %-24.69 %7.63 %36.33 %63.75 %
Sector12.56 %-9.92 %7.24 %28.08 %41.03 %
Rank within sector6 / 2929 / 2913 / 276 / 243 / 23
Quartile th1 st4 th2 nd1 st1 st

Risk statistics

Alpha-4.02
Beta1.63
Sharpe0.14
Volatility27.26
Tracking error14.5
Information ratio-0.06
R-Squared0.86

Price movement

52 week high469.29
52 week low338.96
Current bid price0
Current offer price0
Current mid price443.12

Holdings by region

  • 97.9% USA
  • 1.4% Others
  • 0.7% Money Market

Holdings by sector

  • 57.9% Health Care
  • 16% Pharmaceuticals
  • 14.3% Healthcare & Medical Products
  • 7.3% Others
  • 3.8% Biotechnology/Medical
  • 0.7% Money Market

Holdings by asset type

  • 97.9% US Equities
  • 1.4% Money Market
  • 0.7% International Equities

Individual holdings

  • 9% CELGENE CORP
  • 8.1% GILEAD SCIENCES INC
  • 8% REGENERON PHARMACEUTICALS INC
  • 7.5% BIOGEN INC
  • 7.4% AMGEN INC
  • 4.7% ALEXION PHARMACEUTICALS INC
  • 4.4% VERTEX PHARMACEUTICAL
  • 4.2% INCYTE CORP
  • 3.8% ILLUMINA INC
  • 2.5% MYLAN INC